Immunovant (IMVT) Retained Earnings (2018 - 2026)

Immunovant has reported Retained Earnings for 9 years, with the latest figure at -$1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 40.79% year-over-year to -$1.7 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.7 billion (down 40.79% YoY), and the FY2026 full-year result was -$1.7 billion, down 40.79% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.7 billion, down from -$1.6 billion in the prior quarter.
• The five-year high for Retained Earnings was $1.8 million in Q2 2024, with the low at -$1.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$738.9 million across 5 years, with a median of -$750.4 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 230.07% — and 2024, when it sank 199310.92%.
• Immunovant's Retained Earnings stood at $1.4 million in 2022, then sank by 54356.25% to -$750.4 million in 2023, then plunged by 51.0% to -$1.1 billion in 2024, then slumped by 40.97% to -$1.6 billion in 2025, then slipped by 9.25% to -$1.7 billion in 2026.
• The last three Retained Earnings figures came in at -$1.7 billion (Q1 2026), -$1.6 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.